This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

EV1111

Aripiprazole-induced pathological gambling in first-episode psychosis: reversible after switching to paliperidone

ARIPIPRAZOLE-INDUCED PATHOLOGICAL GAMBLING IN FIRST-EPISODE PSYCHOSIS: REVERSIBLE AFTER SWITCH TO PALIPERIDONE

Pathological gambling that emerged during maintenance treatment with long-acting aripiprazole resolved after switching to paliperidone, with full remission sustained for more than six months.

The aim is to report, through a case study, the risk of impulse control disorders associated with the partial dopaminergic agonist activity of aripiprazole, which is widely used in first-episode psychosis because of its favorable tolerability profile and long-acting injectable (LAI) formulation. The case concerns a 26-year-old man whose psychotic symptoms achieved full remission with oral aripiprazole 20 mg/day and who was switched to LAI aripiprazole 400 mg/month to improve treatment adherence; he had a history of cannabis use disorder that entered full remission after the onset of psychosis and remained stable throughout follow-up. Clinical follow-up included psychopathological assessment and evaluation of gambling symptoms using the Problem Gambling Severity Index criteria. Five months after starting LAI aripiprazole, the patient developed progressively increasing repetitive betting behavior, intrusive gambling-related thoughts, loss of control over gambling urges, and financial losses. No prior history of gambling disorder or any other impulse control disorder was documented, and psychotic symptoms remained fully controlled. Given the temporal relationship with aripiprazole exposure, treatment was switched to paliperidone, resulting in marked improvement in gambling symptoms, sustained full remission for more than six months, and no recurrence of psychotic symptoms. This case highlights the need for continued behavioral monitoring in young, clinically stable patients receiving dopaminergic partial agonists and demonstrates that clinical stability does not rule out adverse effects involving impulse control.

Tüm WCP 2026 özetleri